Posts

Showing posts with the label HTA
Show all
Image

EU Joint Clinical Assessment after the first reports: How should companies interpret the findings?

Image

Anti-Amyloid Drugs in Alzheimer’s: Breakthrough, Dead End, or Reimbursement Reality Check?

Image

MFN Pricing and the “Global Launch Freeze”: A More Measured Perspective

Image

GLP-1s and the Rise of Consumer-Led Pharma: What the Obesity Market Signals for the Future of Access

Image

Access To The New Alzheimer's Drugs: Why HTA Bodies Are Saying No

Image

Taking on the access hurdles for orphan drugs: preparing for EU HTA